Jim Simons
SXTC icon

Jim Simons’s China SXT Pharmaceuticals SXTC Stock Holding History

Jim Simons’s Portfolio SXTC Stock Details SXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4
Closed -$69.9K – 3744
2025
Q3 		$69.9K Buy
+4
New +$79K ﹤0.01% 3301
2023
Q3 		– Hold
0
– -$2K – 4098
2023
Q2 		– Hold
0
– – – 3862
2023
Q1 		– Hold
0
– – – 3887
2022
Q4 		– Hold
0
– -$17K – 4404
2022
Q3 		– Hold
0
– – – 3914
2022
Q2 		– Hold
0
– – – 3990
2022
Q1 		– Hold
0
– – – 3754
2021
Q4 		– Hold
0
– – – 3849
2021
Q1 		– Hold
0
– -$218K – 3693
2020
Q4 		– Hold
0
– – – 3108
2020
Q3 		– Hold
0
– – – 3249
2020
Q2 		– Hold
0
– – – 2885
2020
Q1 		– Hold
0
– – – 2930
2019
Q4 		– Hold
0
– – – 3256
2019
Q3 		– Hold
0
– – – 3365

Other funds holding SXTC

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jim Simons's SXTC Position: Q4 2025 in Review

Jim Simons sold out of China SXT Pharmaceuticals (SXTC) in Q4 2025, closing a stake of 4 shares — an estimated $69.9K sold.

Jim Simons first reported a position in SXTC in Q3 2025 and held it in 1 quarter. The position peaked at $69.9K in Q3 2025. 5 funds tracked by Wall St. Rank hold SXTC as of Q4 2025.

  • Jim Simons reported no remaining China SXT Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Jim Simons sold 4 China SXT Pharmaceuticals shares in Q4 2025, an estimated $69.9K.
  • Jim Simons first reported a position in China SXT Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Jim Simons's China SXT Pharmaceuticals position peaked at $69.9K in Q3 2025.
  • 5 funds tracked by Wall St. Rank held China SXT Pharmaceuticals as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.